Bristol-Myers Squibb (NY:BMY)

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

3 Unpopular Stocks That Concern Us

January 28, 2026

Bristol-Myers Squibb Co (NYSE:BMY) Shows Strong Technical Setup for Potential Breakout ↗

January 28, 2026

Via Chartmill

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth ↗

January 17, 2026

Via Chartmill

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗

January 24, 2026

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term. ↗

Topics ETFs Intellectual Property World Trade

January 23, 2026

Artificial intelligence may be all the rage in the technology sector, but it's also having a huge impact on healthcare.

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

Topics Artificial Intelligence

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗

January 23, 2026

Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth

January 22, 2026

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the...

Large, well-run dividend-paying companies with attractive yields are out there if you look hard enough.

Topics Earnings Economy Intellectual Property

The Best Stocks to Invest $1,000 in Right Now ↗

January 21, 2026

They are unlikely to resort to dividend cuts anytime soon.

Topics Intellectual Property

2 Dividend Stocks to Buy and Hold For 10 Years ↗

January 19, 2026

As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic...

Topics Intellectual Property

2 Buffett Stocks to Load Up On—And 1 to Ditch ↗

January 19, 2026

Via MarketBeat

The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape

January 15, 2026

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Topics Economy Intellectual Property

Thursday's session: gap up and gap down stock in the S&P500 index ↗

January 15, 2026

Via Chartmill

3 Value Stocks That Fall Short

January 14, 2026

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural...

3 S&P 500 Stocks Walking a Fine Line

January 13, 2026

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Topics Stocks

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

January 13, 2026

The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The...

Topics Artificial Intelligence Economy Intellectual Property

The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance

January 12, 2026

Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

Topics Artificial Intelligence Intellectual Property

January 09, 2026

In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Topics Intellectual Property

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Topics Artificial Intelligence Economy Intellectual Property

3 Drug Stocks to Buy at a Discount ↗

January 07, 2026

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

Discover which S&P500 stocks are making waves on Wednesday. ↗

January 07, 2026

Via Chartmill

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

This ETF could produce robust total returns in 2026 and beyond.

Topics Economy Intellectual Property World Trade

1 Top ETF I Plan to Load Up on in 2026 ↗

January 02, 2026

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

Topics ETFs Stocks

January 01, 2026

As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the...

Topics Intellectual Property

2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

December 31, 2025

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

Topics Stocks

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...